|
1. Biologie
|
|
|
|
1.4 Biologie - Technos
|
|
|
|
2.7 Etiologie - Obésité
|
|
|
Teen obesity tied to increased risk of pancreatic cancer [Reuters]
|
|
|
|
|
|
Researchers
followed nearly 2 million men and women for more than 20 years.
Compared to participants with normal weight as teens, men who were obese
as adolescents had more than three times the risk of pancreatic cancer
in adulthood, and obese teen girls had more than four times the risk.
|
|
|
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
Risk stratification in breast screening: A word of caution [Journal of Medical Screening]
|
|
|
|
|
|
We
would be prudent to wait for empirical results from trials such as
MyPeBS before taking a view about the effectiveness, practicality and
cost-effectiveness of risk stratification in determining eligibility for
breast screening. As things stand at present, the need for further risk
stratification is not established. The objections to this are not
simply attitudinal: there are unresolved scientific and public health
objections.
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
5.2.3 Pharma - économie
|
|
|
Former Aveo CFO found guilty of misleading investors about prospects for cancer drug [FiercePharma]
|
|
|
|
|
|
The
saga started in May 2012, when Aveo met with the FDA to discuss results
from a pivotal trial of tivozanib. The agency expressed concerns about
deaths among patients in the trial who were taking the experimental drug
and recommended the company conduct a second randomized trial. The SEC
alleged that Aveo did not fully communicate that news to investors, even
as the company was planning the second trial.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
|
|
|
FDA approves new treatment for patients with acute myeloid leukemia [FDA]
|
|
|
|
|
|
The
trial measured overall survival (OS) from the date of randomization to
death from any cause. Results demonstrated a significant improvement in
OS in patients treated with Daurismo (glasdegib). The median OS was 8.3
months for patients treated with Daurismo plus LDAC compared with 4.3
months for patients treated with LDAC only.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
To catch misconduct, journals are hiring research integrity czars [STAT]
|
|
|
|
|
|
At
PLOS, Hoch’s team, which was created in January, sees everything from
concerns about data, to failure to disclose important conflicts of
interest, to authorship disputes, and more. “If you wrote a list of
potential ethical issues, we’ve probably seen everything on it,” she
said, noting that the largest slices of the pie are image manipulation
and data concerns.
|
|
|
|
|
|